AMY BHEIMBERGERAMY B HEIMBERGER9035HEIMBERGER, AMY BProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson25342601Congdon KL, Gedeon PC, Suryadevara CM, Caruso HG, Cooper LJ, Heimberger AB, Sampson JHNeuro-oncologyEpidermal growth factor receptor and variant III targeted immunotherapy. Neuro Oncol. 2014 Oct; 16 Suppl 8:viii20-5.Neuro Oncol2014-10-01T00:00:002014Epidermal growth factor receptor and variant III targeted immunotherapy.25398845Fecci PE, Heimberger AB, Sampson JHClinical cancer research : an official journal of the American Association for Cancer ResearchImmunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res. 2014 Nov 15; 20(22):5620-9.Clin Cancer Res2014-11-15T00:00:002014Immunotherapy for primary brain tumors: no longer a matter of privilege.25302990Gressot LV, Doucette TA, Yang Y, Fuller GN, Heimberger AB, B?gler O, Rao A, Latha K, Rao GInternational journal of cancerSignal transducer and activator of transcription 5b drives malignant progression in a PDGFB-dependent proneural glioma model by suppressing apoptosis. Int J Cancer. 2015 May 01; 136(9):2047-54.Int J Cancer2014-10-23T00:00:002014Signal transducer and activator of transcription 5b drives malignant progression in a PDGFB-dependent proneural glioma model by suppressing apoptosis.25465288Kong LY, Wei J, Haider AS, Liebelt BD, Ling X, Conrad CA, Fuller GN, Levine NB, Priebe W, Sawaya R, Heimberger ABJournal of neuroimmunologyTherapeutic targets in subependymoma. J Neuroimmunol. 2014 Dec 15; 277(1-2):168-75.J Neuroimmunol2014-10-31T00:00:002014Therapeutic targets in subependymoma.1400 Holcombe BlvdHouston77030-4008TXAuthorship 1636071Authorship 1637861Authorship 1639272Authorship 1719171Authorship 1719304Authorship 1724641Authorship 1729362Authorship 1739011Authorship 1739321Authorship 17400514Authorship 1743772Authorship 1766131Authorship 1766628Authorship 1776105Authorship 1780236Authorship 1783006Authorship 1791324Authorship 1791488Authorship 17948812Authorship 1796384Authorship 17992110Authorship 1799431Authorship 18006013Authorship 1805534Authorship 18057114Authorship 1808531Authorship 1809828Authorship 1809838Authorship 18157711Authorship 1820404Authorship 18212011Authorship 1822631Authorship 1828241Authorship 1833881Authorship 18344114Authorship 1834744Authorship 1835262Authorship 18368614Authorship 1839854Authorship 1840933Authorship 1845924Authorship 1848168Authorship 1850214Authorship 18515313Authorship 1854602Authorship 18566510Authorship 18671713Authorship 1869201Authorship 18692218Authorship 18714212Authorship 1874034Authorship 1889373Authorship 18906110Authorship 1893719Authorship 18984910Authorship 19109212Authorship 1919228Authorship 1925543Authorship 19256322Authorship 19516519Authorship 1952079Authorship 19573110Authorship 19593417Experimental TherapeuticsNeuro-OncologyMD AndersonRAYMOND ESAWAYARAYMOND E SAWAYA8456SAWAYA, RAYMOND EProfessorGREGORY NFULLERGREGORY N FULLER8573FULLER, GREGORY NProfessorWALDEMARPRIEBEWALDEMAR PRIEBE8492PRIEBE, WALDEMARProfessor12.22190.0038545555research areas6.053840.0222391134coauthor of373.18452.841459similar to11235selected publicationsJOHN FREDERICKDE GROOTJOHN FREDERICK DE GROOT9019DE GROOT, JOHN FREDERICKProfessorSHERISE DESIREEFERGUSONSHERISE DESIREE FERGUSON9726FERGUSON, SHERISE DESIREEAssistant Professor25586468Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JHNeuro-oncologyA phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015 Jun; 17(6):854-61.Neuro Oncol2015-01-13T00:00:002015A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.25971300Yan J, Kong LY, Hu J, Gabrusiewicz K, Dibra D, Xia X, Heimberger AB, Li SJournal of the National Cancer InstituteFGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. J Natl Cancer Inst. 2015 Aug; 107(8).J Natl Cancer Inst2015-05-13T00:00:002015FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.3293564Heimberger A, Eisenstark ABiochemical and biophysical research communicationsCompartmentalization of catalases in Escherichia coli. Biochem Biophys Res Commun. 1988 Jul 15; 154(1):392-7.Biochem Biophys Res Commun1988-07-15T00:00:001988Compartmentalization of catalases in Escherichia coli.Authorship 2806089Authorship 2806815Authorship 2807456Authorship 2807565Authorship 2808202Authorship 2808941Authorship 28091217Authorship 2809807Authorship 281022111385868Hsieh CS, Heimberger AB, Gold JS, O'Garra A, Murphy KMProceedings of the National Academy of Sciences of the United States of AmericaDifferential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proc Natl Acad Sci U S A. 1992 Jul 01; 89(13):6065-9.Proc Natl Acad Sci U S A1992-07-01T00:00:001992Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system.Authorship 2950298Authorship 29976712Authorship 300382325700834Ferguson SD, Srinivasan VM, Heimberger ABJournal of neuro-oncologyThe role of STAT3 in tumor-mediated immune suppression. J Neurooncol. 2015 Jul; 123(3):385-94.J Neurooncol2015-02-22T00:00:002015The role of STAT3 in tumor-mediated immune suppression.25832656Gong AH, Wei P, Zhang S, Yao J, Yuan Y, Zhou AD, Lang FF, Heimberger AB, Rao G, Huang SCancer researchFoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells. Cancer Res. 2015 Jun 01; 75(11):2337-48.Cancer Res2015-04-01T00:00:002015FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells.26330164Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, Lee DA, Heimberger AB, Champlin RE, Cooper LJCancer researchTuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res. 2015 Sep 01; 75(17):3505-18.Cancer Res2015-09-01T00:00:002015Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.26516226Nduom EK, Weller M, Heimberger ABNeuro-oncologyImmunosuppressive mechanisms in glioblastoma. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii9-vii14.Neuro Oncol2015-11-01T00:00:002015Immunosuppressive mechanisms in glioblastoma.74Professor10Assistant Professor14Associate Professor6Adjunct Professor16573834Hussain SF, Yang D, Suki D, Grimm E, Heimberger ABJournal of translational medicineInnate immune functions of microglia isolated from human glioma patients. J Transl Med. 2006 Mar 30; 4:15.J Transl Med2006-03-30T00:00:002006Innate immune functions of microglia isolated from human glioma patients.27163741Caruso HG, Torikai H, Zhang L, Maiti S, Dai J, Do KA, Singh H, Huls H, Lee DA, Champlin RE, Heimberger AB, Cooper LJJournal of immunotherapy (Hagerstown, Md. : 1997)Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor. J Immunother. 2016 06; 39(5):205-17.J Immunother2016-06-01T00:00:002016Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.26967252Zhao H, Heimberger AB, Lu Z, Wu X, Hodges TR, Song R, Shen JOncotargetMetabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes. Oncotarget. 2016 Apr 12; 7(15):20486-95.Oncotarget2016-04-12T00:00:002016Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes.12489674Heimberger AB, Wiltshire RN, Bronec R, McLendon RE, Cummings TJClinical neuropathologyBiphasic malignant meningioma: a comparative genomic hybridization study. Clin Neuropathol. 2002 Nov-Dec; 21(6):258-64.Clin Neuropathol2002-11-01T00:00:002002Biphasic malignant meningioma: a comparative genomic hybridization study.15009722McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, Shtivelband M, Bar-Eli MThe Journal of investigative dermatologyImatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol. 2004 Feb; 122(2):400-5.J Invest Dermatol2004-02-01T00:00:002004Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.17575219Barnett JA, Urbauer DL, Murray GI, Fuller GN, Heimberger ABClinical cancer research : an official journal of the American Association for Cancer ResearchCytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target. Clin Cancer Res. 2007 Jun 15; 13(12):3559-67.Clin Cancer Res2007-06-15T00:00:002007Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target.27246830Xue J, Zhou A, Wu Y, Morris SA, Lin K, Amin S, Verhaak R, Fuller G, Xie K, Heimberger AB, Huang SCancer researchmiR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis. Cancer Res. 2016 07 15; 76(14):4293-304.Cancer Res2016-05-31T00:00:002016miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis.18991807Heimberger AB, Priebe WRecent patents on CNS drug discoverySmall molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers. Recent Pat CNS Drug Discov. 2008 Nov; 3(3):179-88.Recent Pat CNS Drug Discov2008-11-01T00:00:002008Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers.14695161McGary EC, Heimberger A, Mills L, Weber K, Thomas GW, Shtivelband M, Lev DC, Bar-Eli MClinical cancer research : an official journal of the American Association for Cancer ResearchA fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res. 2003 Dec 15; 9(17):6560-6.Clin Cancer Res2003-12-15T00:00:002003A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo.19591631Heimberger AB, Sampson JHExpert opinion on biological therapyThe PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther. 2009 Aug; 9(8):1087-98.Expert Opin Biol Ther2009-08-01T00:00:002009The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.19744042Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, Sampson JHBrain pathology (Zurich, Switzerland)EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol. 2009 Oct; 19(4):713-23.Brain Pathol2009-10-01T00:00:002009EGFRvIII-targeted vaccination therapy of malignant glioma.19944970Kanaly CW, Ding D, Heimberger AB, Sampson JHNeurosurgery clinics of North AmericaClinical applications of a peptide-based vaccine for glioblastoma. Neurosurg Clin N Am. 2010 Jan; 21(1):95-109.Neurosurg Clin N Am2010-01-01T00:00:002010Clinical applications of a peptide-based vaccine for glioblastoma.20068105Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Sawaya R, Lang FF, Heimberger ABClinical cancer research : an official journal of the American Association for Cancer ResearchGlioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res. 2010 Jan 15; 16(2):461-73.Clin Cancer Res2010-01-12T00:00:002010Glioma-associated cancer-initiating cells induce immunosuppression.16194456Brem SS, Bierman PJ, Black P, Blumenthal DT, Brem H, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Fine HA, Friedman A, Glass J, Grossman SA, Heimberger AB, Junck L, Levin V, Loeffler JJ, Maor MH, Narayana A, Newton HB, Olivi A, Portnow J, Prados M, Raizer JJ, Rosenfeld SS, Shrieve DC, Sills AK, Spence AM, Vrionis FD, National Comprehensive Cancer NetworkJournal of the National Comprehensive Cancer Network : JNCCNCentral nervous system cancers: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2005 Sep; 3(5):644-90.J Natl Compr Canc Netw2005-09-01T00:00:002005Central nervous system cancers: Clinical Practice Guidelines in Oncology.20737294Hatiboglu MA, Wei J, Wu AS, Heimberger ABTargeted oncologyImmune therapeutic targeting of glioma cancer stem cells. Target Oncol. 2010 Sep; 5(3):217-27.Target Oncol2010-08-25T00:00:002010Immune therapeutic targeting of glioma cancer stem cells.20921210Kong LY, Wu AS, Doucette T, Wei J, Priebe W, Fuller GN, Qiao W, Sawaya R, Rao G, Heimberger ABClinical cancer research : an official journal of the American Association for Cancer ResearchIntratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res. 2010 Dec 01; 16(23):5722-33.Clin Cancer Res2010-10-04T00:00:002010Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.16236164Heimberger AB, Suki D, Yang D, Shi W, Aldape KJournal of translational medicineThe natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med. 2005 Oct 19; 3:38.J Transl Med2005-10-19T00:00:002005The natural history of EGFR and EGFRvIII in glioblastoma patients.27742110Salzillo TC, Hu J, Nguyen L, Whiting N, Lee J, Weygand J, Dutta P, Pudakalakatti S, Millward NZ, Gammon ST, Lang FF, Heimberger AB, Bhattacharya PKMagnetic resonance imaging clinics of North AmericaInterrogating Metabolism in Brain Cancer. Magn Reson Imaging Clin N Am. 2016 Nov; 24(4):687-703.Magn Reson Imaging Clin N Am2016-11-01T00:00:002016Interrogating Metabolism in Brain Cancer.21490182Dziurzynski K, Wei J, Qiao W, Hatiboglu MA, Kong LY, Wu A, Wang Y, Cahill D, Levine N, Prabhu S, Rao G, Sawaya R, Heimberger ABClinical cancer research : an official journal of the American Association for Cancer ResearchGlioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res. 2011 Jul 15; 17(14):4642-9.Clin Cancer Res2011-04-13T00:00:002011Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype.15701277Heimberger AB, Wang E, McGary EC, Hess KR, Henry VK, Shono T, Cohen Z, Gumin J, Sawaya R, Conrad CA, Lang FFNeuro-oncologyMechanisms of action of rapamycin in gliomas. Neuro Oncol. 2005 Jan; 7(1):1-11.Neuro Oncol2005-01-01T00:00:002005Mechanisms of action of rapamycin in gliomas.Authorship 374509915746047Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape KClinical cancer research : an official journal of the American Association for Cancer ResearchPrognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005 Feb 15; 11(4):1462-6.Clin Cancer Res2005-02-15T00:00:002005Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.21792892Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger ABInternational journal of cancerThe tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer. 2012 Jul 01; 131(1):8-17.Int J Cancer2011-08-24T00:00:002011The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.17538175Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG, Buckner JC, James CD, Aldape KJournal of clinical oncology : official journal of the American Society of Clinical OncologyEpidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007 Jun 01; 25(16):2288-94.J Clin Oncol2007-06-01T00:00:002007Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.17908822Paz N, Levanon EY, Amariglio N, Heimberger AB, Ram Z, Constantini S, Barbash ZS, Adamsky K, Safran M, Hirschberg A, Krupsky M, Ben-Dov I, Cazacu S, Mikkelsen T, Brodie C, Eisenberg E, Rechavi GGenome researchAltered adenosine-to-inosine RNA editing in human cancer. Genome Res. 2007 Nov; 17(11):1586-95.Genome Res2007-10-01T00:00:002007Altered adenosine-to-inosine RNA editing in human cancer.17942891Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger ABCancer researchA novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007 Oct 15; 67(20):9630-6.Cancer Res2007-10-15T00:00:002007A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients.17522861Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger ABCancer immunology, immunotherapy : CIIPreferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother. 2008 Jan; 57(1):123-31.Cancer Immunol Immunother2007-05-24T00:00:002007Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.18079360Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell DA, Bigner DD, Sampson JHNeuro-oncologyImmunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol. 2008 Feb; 10(1):98-103.Neuro Oncol2007-12-13T00:00:002007Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.18539480Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DDSeminars in immunologyTumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol. 2008 Oct; 20(5):267-75.Semin Immunol2008-06-09T00:00:002008Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.18594817Wei J, DeAngulo G, Sun W, Hussain SF, Vasquez H, Jordan J, Weinberg J, Wolff J, Koshkina N, Heimberger ABCancer immunology, immunotherapy : CIITopotecan enhances immune clearance of gliomas. Cancer Immunol Immunother. 2009 Feb; 58(2):259-70.Cancer Immunol Immunother2008-07-02T00:00:002008Topotecan enhances immune clearance of gliomas.18492461Brem SS, Bierman PJ, Black P, Brem H, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Glass J, Grossman SA, Heimberger AB, Junck L, Linette GP, Loeffler JJ, Maor MH, Moots P, Mrugala M, Nabors LB, Newton HB, Olivi A, Portnow J, Prados M, Raizer JJ, Shrieve DC, Sills AKJournal of the National Comprehensive Cancer Network : JNCCNCentral nervous system cancers. J Natl Compr Canc Netw. 2008 May; 6(5):456-504.J Natl Compr Canc Netw2008-05-01T00:00:002008Central nervous system cancers.2125367Murphy KM, Heimberger AB, Loh DYScience (New York, N.Y.)Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science. 1990 Dec 21; 250(4988):1720-3.Science1990-12-21T00:00:001990Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo.18698034Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, Hiraoka N, Fuller GNClinical cancer research : an official journal of the American Association for Cancer ResearchIncidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008 Aug 15; 14(16):5166-72.Clin Cancer Res2008-08-15T00:00:002008Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.18775433Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE, Friedman HS, Bigner DD, Sampson JHJournal of immunological methodsDetection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods. 2008 Nov 30; 339(1):74-81.J Immunol Methods2008-09-04T00:00:002008Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.19002459Kong LY, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, Fokt I, Weinberg J, Rao G, Grimm E, Priebe W, Heimberger ABCancer immunology, immunotherapy : CIIA novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother. 2009 Jul; 58(7):1023-32.Cancer Immunol Immunother2008-11-11T00:00:002008A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.19088040Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N, Priebe W, Sawaya R, Heimberger ABClinical cancer research : an official journal of the American Association for Cancer ResearchThe incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res. 2008 Dec 15; 14(24):8228-35.Clin Cancer Res2008-12-15T00:00:002008The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas.19536297Murat A, Migliavacca E, Hussain SF, Heimberger AB, Desbaillets I, Hamou MF, R?egg C, Stupp R, Delorenzi M, Hegi MEPloS oneModulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One. 2009 Jun 17; 4(6):e5947.PLoS One2009-06-17T00:00:002009Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia.27841882Shingu T, Ho AL, Yuan L, Zhou X, Dai C, Zheng S, Wang Q, Zhong Y, Chang Q, Horner JW, Liebelt BD, Yao Y, Hu B, Chen Y, Fuller GN, Verhaak RG, Heimberger AB, Hu JNature geneticsQki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nat Genet. 2017 01; 49(1):75-86.Nat Genet2016-11-14T00:00:002016Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation.19825799Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS, Bigner DDMolecular cancer therapeuticsAn epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009 Oct; 8(10):2773-9.Mol Cancer Ther2009-10-01T00:00:002009An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.19900287Humphries W, Wang Y, Qiao W, Reina-Ortiz C, Abou-Ghazal MK, Crutcher LM, Wei J, Kong LY, Sawaya R, Rao G, Weinberg J, Prabhu SS, Fuller GN, Heimberger ABJournal of translational medicineyuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. J Transl Med. 2009 Nov 09; 7:92.J Transl Med2009-11-09T00:00:002009yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients.20053772Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, Sawaya R, Lang FF, Heimberger ABMolecular cancer therapeuticsGlioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther. 2010 Jan; 9(1):67-78.Mol Cancer Ther2010-01-06T00:00:002010Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway.20214040Heimberger AB, Kong LY, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Wei J, Qiao W, Schmittling RJ, Archer GE, Sampson JH, Hiraoka N, Priebe W, Fuller GN, Sawaya RClinical neurosurgeryThe role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor. Clin Neurosurg. 2009; 56:98-106.Clin Neurosurg2009-01-01T00:00:002009The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.20667896Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, Sawaya R, Heimberger ABNeuro-oncologyGlioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010 Nov; 12(11):1113-25.Neuro Oncol2010-07-28T00:00:002010Glioma cancer stem cells induce immunosuppressive macrophages/microglia.20388845Kong LY, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang EC, Hailemichael Y, Fokt I, Jayakumar A, Qiao W, Fuller GN, Overwijk WW, Priebe W, Heimberger ABClinical cancer research : an official journal of the American Association for Cancer ResearchInhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res. 2010 May 01; 16(9):2550-61.Clin Cancer Res2010-04-13T00:00:002010Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model.21149252Heimberger AB, Sampson JHNeuro-oncologyImmunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol. 2011 Jan; 13(1):3-13.Neuro Oncol2010-12-10T00:00:002010Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?JASONHUSEJASON HUSE12747HUSE, JASONAssociate Professor21593697Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, Macdonald DR, Van den Bent MJ, Chang SMNeurosurgeryApplication of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2012 Jan; 70(1):234-43; discussion 243-4.Neurosurgery2012-01-01T00:00:002012Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.20921459Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, Bigner DDJournal of clinical oncology : official journal of the American Society of Clinical OncologyImmunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010 Nov 01; 28(31):4722-9.J Clin Oncol2010-10-04T00:00:002010Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.22753228Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, Aldape K, Priebe W, B?gler O, Heimberger AB, Rao GNeuro-oncologySignal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol. 2012 Sep; 14(9):1136-45.Neuro Oncol2012-06-29T00:00:002012Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma.26973881Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, Liebelt BD, Yaghi NK, Ezhilarasan R, Huang N, Weinberg JS, Prabhu SS, Rao G, Sawaya R, Langford LA, Bruner JM, Fuller GN, Bar-Or A, Li W, Colen RR, Curran MA, Bhat KP, Antel JP, Cooper LJ, Sulman EP, Heimberger ABJCI insightGlioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016; 1(2).JCI Insight2016-02-25T00:00:002016Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.23394340Wu AS, Trinh VT, Suki D, Graham S, Forman A, Weinberg JS, McCutcheon IE, Prabhu SS, Heimberger AB, Sawaya R, Wang X, Qiao W, Hess K, Lang FFJournal of neurosurgeryA prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. J Neurosurg. 2013 Apr; 118(4):873-883.J Neurosurg2013-02-08T00:00:002013A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors.23591978Sanchez-Perez L, Choi BD, Reap EA, Sayour EJ, Norberg P, Schmittling RJ, Archer GE, Herndon JE, Mitchell DA, Heimberger AB, Bigner DD, Sampson JHCancer immunology, immunotherapy : CIIBLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunol Immunother. 2013 Jun; 62(6):983-7.Cancer Immunol Immunother2013-04-17T00:00:002013BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.Authorship 842775Authorship 842813Authorship 844045Authorship 845220Authorship 847476Authorship 850151Authorship 851254Authorship 852583Authorship 853327Authorship 853476Authorship 853914Authorship 854397Authorship 854421Authorship 855287Authorship 855856Authorship 856324Authorship 856548Authorship 858975Authorship 860062Authorship 860260Authorship 862890Authorship 863342Authorship 865649Authorship 865799Authorship 866875Authorship 86767028284220Zhao H, Shen J, Hodges TR, Song R, Fuller GN, Heimberger ABMolecular cancerSerum microRNA profiling in patients with glioblastoma: a survival analysis. Mol Cancer. 2017 03 11; 16(1):59.Mol Cancer2017-03-11T00:00:002017Serum microRNA profiling in patients with glioblastoma: a survival analysis.Journal of Clinical OncologyReply to M.C. Chamberlain. Journal of Clinical Oncology. 29.Reply to M.C. ChamberlainNeuro-OncologyPD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology. 18:195-205.PD-L1 expression and prognostic impact in glioblastomaOncoImmunologyMicroRNAs as novel immunotherapeutics. OncoImmunology. 2.MicroRNAs as novel immunotherapeuticsNeuro-OncologyMiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro-Oncology. 18:639-648.MiR-138 exerts anti-glioma efficacy by targeting immune checkpointsInternational Reviews of ImmunologyThe Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant. International Reviews of Immunology. The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated ProcoagulantOncoImmunologyTipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression. OncoImmunology. Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppressionOncotargetDiscovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells. Oncotarget. 7:72021-72032.Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cellsLetters in Drug Design and DiscoverySynergistic effect of immunotherapy and chemotherapy in cancers. Letters in Drug Design and Discovery. 3:513-523.Synergistic effect of immunotherapy and chemotherapy in cancersImmunotherapyCytomegalovirus-targeted immunotherapy and glioblastoma. Immunotherapy. 8:413-423.Cytomegalovirus-targeted immunotherapy and glioblastomaPrinciples of immunotherapy. 163-181.Principles of immunotherapyJournal of Translational MedicineThe natural history of EGFR and EGFRvIII in glioblastoma patients. Journal of Translational Medicine. 3.The natural history of EGFR and EGFRvIII in glioblastoma patientsJournal of Clinical OncologyReply to J.W. Locasale et al. Journal of Clinical Oncology. 30:338-339.Reply to J.W. Locasale et alJournal of ImmunotherapyRedirecting T-cell specificity to EGFR using mRNA to self-limit expression of chimeric antigen receptor. Journal of Immunotherapy. 39:205-217.Redirecting T-cell specificity to EGFR using mRNA to self-limit expression of chimeric antigen receptorJournal of Clinical OncologyReply to M.S. Lesniak. Journal of Clinical Oncology. 29:3105-3106.Reply to M.S. LesniakJournal of Neuro-OncologyThe role of STAT3 in tumor-mediated immune suppression. Journal of Neuro-Oncology. 123:385-394.The role of STAT3 in tumor-mediated immune suppressionOncotargetMetabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes. Oncotarget. 7:20486-20495.Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypesOncoImmunologyPrioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology. Prioritization schema for immunotherapy clinical trials in glioblastomaMagnetic Resonance Imaging Clinics of North AmericaInterrogating Metabolism in Brain Cancer. Magnetic Resonance Imaging Clinics of North America. 24:687-703.Interrogating Metabolism in Brain CancerOncotargetGBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. 7:69466-69478.GBM-associated mutations and altered protein expression are more common in young patientsLetters in Drug Design and DiscoveryThe role of glioma microenvironment in immune modulation. Letters in Drug Design and Discovery. 3:443-453.The role of glioma microenvironment in immune modulationCancer Immunology, ImmunotherapyErratum. Cancer Immunology, Immunotherapy. 57:133.ErratumNature GeneticsQki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nature Genetics. 49:75-86.Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradationCancer ResearchmiR-182-5p induced by STAT3 activation promotes glioma tumorigenesis. Cancer Research. 76:4293-4304.miR-182-5p induced by STAT3 activation promotes glioma tumorigenesisJournal of Translational MedicineInnate immune functions of microglia isolated from human glioma patients. Journal of Translational Medicine. 4.Innate immune functions of microglia isolated from human glioma patientsNeuro-OncologyImmune checkpoint blockade as a potential therapeutic target. Neuro-Oncology. 18:1357-1366.Immune checkpoint blockade as a potential therapeutic targetNeuro-OncologyA phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma. Neuro-Oncology. 17:854-861.A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma23013619de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, Qiao W, Heimberger ABOncotargetModulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget. 2012 Sep; 3(9):1036-48.Oncotarget2012-09-01T00:00:002012Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma.28687375Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Sulman E, McCutcheon IE, Azeem S, Cahill D, Tatsui C, Heimberger AB, Ferguson S, Ghia A, Demonte F, Raza S, Guha-Thakurta N, Yang J, Sawaya R, Hess KR, Rao GThe Lancet. OncologyPost-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1040-1048.Lancet Oncol2017-07-04T00:00:002017Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial.14519652Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JHClinical cancer research : an official journal of the American Association for Cancer ResearchEpidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003 Sep 15; 9(11):4247-54.Clin Cancer Res2003-09-15T00:00:002003Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.15671555Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, Bar-Eli MClinical cancer research : an official journal of the American Association for Cancer ResearchLoss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res. 2005 Jan 01; 11(1):267-72.Clin Cancer Res2005-01-01T00:00:002005Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.16221048Hussain SF, Heimberger ABExpert review of anticancer therapyImmunotherapy for human glioma: innovative approaches and recent results. Expert Rev Anticancer Ther. 2005 Oct; 5(5):777-90.Expert Rev Anticancer Ther2005-10-01T00:00:002005Immunotherapy for human glioma: innovative approaches and recent results.16775224Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger ABNeuro-oncologyThe role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006 Jul; 8(3):261-79.Neuro Oncol2006-06-14T00:00:002006The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses.16818690Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barker FG, Fuller GN, Aldape KDClinical cancer research : an official journal of the American Association for Cancer ResearchPrognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res. 2006 Jul 01; 12(13):3935-41.Clin Cancer Res2006-07-01T00:00:002006Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma.18794085Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE, Sampson JH, Priebe W, Heimberger ABClinical cancer research : an official journal of the American Association for Cancer ResearchA novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res. 2008 Sep 15; 14(18):5759-68.Clin Cancer Res2008-09-15T00:00:002008A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.19404147Kim SS, McCutcheon IE, Suki D, Weinberg JS, Sawaya R, Lang FF, Ferson D, Heimberger AB, DeMonte F, Prabhu SSNeurosurgeryAwake craniotomy for brain tumors near eloquent cortex: correlation of intraoperative cortical mapping with neurological outcomes in 309 consecutive patients. Neurosurgery. 2009 May; 64(5):836-45; discussion 345-6.Neurosurgery2009-05-01T00:00:002009Awake craniotomy for brain tumors near eloquent cortex: correlation of intraoperative cortical mapping with neurological outcomes in 309 consecutive patients.19408307Wiemels JL, Wilson D, Patil C, Patoka J, McCoy L, Rice T, Schwartzbaum J, Heimberger A, Sampson JH, Chang S, Prados M, Wiencke JK, Wrensch MInternational journal of cancerIgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. Int J Cancer. 2009 Aug 01; 125(3):680-7.Int J Cancer2009-08-01T00:00:002009IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.2222441Lev?n S, Heimberger A, Eisenstark ABiochemical and biophysical research communicationsCatalase HPI influences membrane permeability in Escherichia coli following near-UV stress. Biochem Biophys Res Commun. 1990 Sep 28; 171(3):1224-8.Biochem Biophys Res Commun1990-09-28T00:00:001990Catalase HPI influences membrane permeability in Escherichia coli following near-UV stress.19944972Humphries W, Wei J, Sampson JH, Heimberger ABNeurosurgery clinics of North AmericaThe role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg Clin N Am. 2010 Jan; 21(1):125-37.Neurosurg Clin N Am2010-01-01T00:00:002010The role of tregs in glioma-mediated immunosuppression: potential target for intervention.21149254Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh JJ, Bigner DD, Heimberger ABNeuro-oncologyGreater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011 Mar; 13(3):324-33.Neuro Oncol2010-12-10T00:00:002010Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.21283755Wei J, Wu A, Kong LY, Wang Y, Fuller G, Fokt I, Melillo G, Priebe W, Heimberger ABPloS oneHypoxia potentiates glioma-mediated immunosuppression. PLoS One. 2011 Jan 20; 6(1):e16195.PLoS One2011-01-20T00:00:002011Hypoxia potentiates glioma-mediated immunosuppression.22319219Dziurzynski K, Chang SM, Heimberger AB, Kalejta RF, McGregor Dallas SR, Smit M, Soroceanu L, Cobbs CS, HCMV and Gliomas SymposiumNeuro-oncologyConsensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 2012 Mar; 14(3):246-55.Neuro Oncol2012-02-08T00:00:002012Consensus on the role of human cytomegalovirus in glioblastoma.22488042Lee I, Fox PS, Ferguson SD, Bassett R, Kong LY, Schacherer CW, Gershenwald JE, Grimm EA, Fuller GN, Heimberger ABOncotargetThe expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget. 2012 Mar; 3(3):336-44.Oncotarget2012-03-01T00:00:002012The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival.28926136Shen J, Hodges TR, Song R, Gong Y, Calin GA, Heimberger AB, Zhao HMolecular carcinogenesisSerum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma. Mol Carcinog. 2018 Jan; 57(1):137-141.Mol Carcinog2017-10-10T00:00:002017Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma.28965162Jacobs DI, Liu Y, Gabrusiewicz K, Tsavachidis S, Armstrong GN, Zhou R, Wei J, Ivan C, Calin G, Molinaro AM, Rice T, Bracci PM, Hansen HM, Wiencke JK, Wrensch MR, Heimberger AB, Bondy MLJournal of neuro-oncologyGermline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. J Neurooncol. 2018 Jan; 136(1):33-39.J Neurooncol2017-09-30T00:00:002017Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients.29603794Shen J, Song R, Hodges TR, Heimberger AB, Zhao HMolecular carcinogenesisIdentification of metabolites in plasma for predicting survival in glioblastoma. Mol Carcinog. 2018 08; 57(8):1078-1084.Mol Carcinog2018-04-16T00:00:002018Identification of metabolites in plasma for predicting survival in glioblastoma.Authorship 8870343Authorship 88784312Authorship 8879086Authorship 88800617Authorship 8880172Authorship 8883274Authorship 88841130Authorship 88847616Authorship 88886010Authorship 88923210Authorship 88954717Authorship 8900036D007167Procedures83233380.374551ImmunotherapyD001932Disorders88848480.292739Brain NeoplasmsD050796Chemicals & Drugs38311200.601372STAT3 Transcription FactorD005910Disorders38619630.43438GliomaAuthorship 9009224Authorship 9035181Authorship 90493610Authorship 90579513Authorship 9058024Authorship 90610320Authorship 90625518Authorship 9067284Authorship 9082846Authorship 9089653Authorship 90973111Authorship 9097407Authorship 91042816Authorship 9124763Authorship 91261720Authorship 91591630Authorship 91658814Authorship 9167478Authorship 9194962Authorship 92028715Authorship 92084814Authorship 92090614Authorship 9216172Authorship 9236744Authorship 92533810Authorship 92546127Authorship 92567212Authorship 9270376Authorship 92716129Authorship 92820912Authorship 93495011Authorship 93776235Authorship 93864914Authorship 9395572022468222Jethwa K, Wei J, McEnery K, Heimberger ABClinical investigationmiRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma. Clin Investig (Lond). 2011 Dec; 1(12):1637-1650.Clin Investig (Lond)2011-12-01T00:00:002011miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma.24083077Heimberger AB, Gilbert M, Rao G, Wei JOncoimmunologyMicroRNAs as novel immunotherapeutics. Oncoimmunology. 2013 Aug 01; 2(8):e25124.Oncoimmunology2013-05-28T00:00:002013MicroRNAs as novel immunotherapeutics.25259408Hu J, Yan J, Rao G, Latha K, Overwijk WW, Heimberger AB, Li SInternational reviews of immunologyThe Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. Int Rev Immunol. 2016 07 03; 35(4):325-339.Int Rev Immunol2014-09-26T00:00:002014The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications.26323609Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger ABNeuro-oncologyPD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016 Feb; 18(2):195-205.Neuro Oncol2015-08-30T00:00:002015PD-L1 expression and prognostic impact in glioblastoma.26973123Ferguson SD, Srinivasan VM, Ghali MG, Heimberger ABImmunotherapyCytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope? Immunotherapy. 2016; 8(4):413-23.Immunotherapy2016-01-01T00:00:002016Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?26948354Liebelt BD, Finocchiaro G, Heimberger ABHandbook of clinical neurologyPrinciples of immunotherapy. Handb Clin Neurol. 2016; 134:163-81.Handb Clin Neurol2016-01-01T00:00:002016Principles of immunotherapy.26658052Wei J, Nduom EK, Kong LY, Hashimoto Y, Xu S, Gabrusiewicz K, Ling X, Huang N, Qiao W, Zhou S, Ivan C, Fuller GN, Gilbert MR, Overwijk W, Calin GA, Heimberger ABNeuro-oncologyMiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro Oncol. 2016 05; 18(5):639-48.Neuro Oncol2015-12-11T00:00:002015MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.27225028Hodges TR, Ferguson SD, Heimberger ABCNS oncologyImmunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncol. 2016 07; 5(3):175-86.CNS Oncol2016-05-26T00:00:002016Immunotherapy in glioblastoma: emerging options in precision medicine.27376157Lin J, Xu K, Wei J, Heimberger AB, Roth JA, Ji LJournal of gene therapyMicroRNA-124 suppresses tumor cell proliferation and invasion by targeting CD164 signaling pathway in non-small cell lung cancer. J Gene Ther. 2016 Feb; 2(1).J Gene Ther2016-02-13T00:00:002016MicroRNA-124 suppresses tumor cell proliferation and invasion by targeting CD164 signaling pathway in non-small cell lung cancer.27370400Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger ABNeuro-oncologyImmune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016 10; 18(10):1357-66.Neuro Oncol2016-07-01T00:00:002016Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.27579614Ferguson SD, Xiu J, Weathers SP, Zhou S, Kesari S, Weiss SE, Verhaak RG, Hohl RJ, Barger GR, Reddy SK, Heimberger ABOncotargetGBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. 2016 Oct 25; 7(43):69466-69478.Oncotarget2016-10-25T00:00:002016GBM-associated mutations and altered protein expression are more common in young patients.27467917Kong LY, Wei J, Fuller GN, Schrand B, Gabrusiewicz K, Zhou S, Rao G, Calin G, Gilboa E, Heimberger ABOncoimmunologyTipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression. Oncoimmunology. 2016 May; 5(5):e1117739.Oncoimmunology2015-12-21T00:00:002015Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression.27471611Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger ABOncoimmunologyPrioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology. 2016 Jun; 5(6):e1145332.Oncoimmunology2016-02-18T00:00:002016Prioritization schema for immunotherapy clinical trials in glioblastoma.27713131Noh H, Yan J, Hong S, Kong LY, Gabrusiewicz K, Xia X, Heimberger AB, Li SOncotargetDiscovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells. Oncotarget. 2016 Nov 01; 7(44):72021-72032.Oncotarget2016-11-01T00:00:002016Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells.27765835Yaghi NK, Wei J, Hashimoto Y, Kong LY, Gabrusiewicz K, Nduom EK, Ling X, Huang N, Zhou S, Kerrigan BC, Levine JM, Fajt VR, Levine G, Porter BF, Marcusson EG, Tachikawa K, Chivukula P, Webb DC, Payne JE, Heimberger ABNeuro-oncologyImmune modulatory nanoparticle therapeutics for intracerebral glioma. Neuro Oncol. 2017 03 01; 19(3):372-382.Neuro Oncol2017-03-01T00:00:002017Immune modulatory nanoparticle therapeutics for intracerebral glioma.28371827Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger ABNeuro-oncologyMutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017 Aug 01; 19(8):1047-1057.Neuro Oncol2017-08-01T00:00:002017Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.28417311Tan AC, Heimberger AB, Menzies AM, Pavlakis N, Khasraw MCurrent oncology reportsImmune Checkpoint Inhibitors for Brain Metastases. Curr Oncol Rep. 2017 Jun; 19(6):38.Curr Oncol Rep2017-06-01T00:00:002017Immune Checkpoint Inhibitors for Brain Metastases.28389997Srinivasan VM, Ferguson SD, Lee S, Weathers SP, Kerrigan BCP, Heimberger ABNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeuticsTumor Vaccines for Malignant Gliomas. Neurotherapeutics. 2017 04; 14(2):345-357.Neurotherapeutics2017-04-01T00:00:002017Tumor Vaccines for Malignant Gliomas.28697342Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauv? CG, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGWCancer cellTumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2017 07 10; 32(1):42-56.e6.Cancer Cell2017-07-10T00:00:002017Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.29254160Narang S, Kim D, Aithala S, Heimberger AB, Ahmed S, Rao D, Rao G, Rao AOncotargetTumor image-derived texture features are associated with CD3 T-cell infiltration status in glioblastoma. Oncotarget. 2017 Nov 24; 8(60):101244-101254.Oncotarget2017-09-05T00:00:002017Tumor image-derived texture features are associated with CD3 T-cell infiltration status in glioblastoma.29316430Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Gabriel Sauv? CE, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGWCancer cellTumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2018 01 08; 33(1):152.Cancer Cell2018-01-08T00:00:002018Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.29387478Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MAESMO openRetrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open. 2018; 3(1):e000283.ESMO Open2018-01-24T00:00:002018Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.29846894Everson RG, Hashimoto Y, Freeman JL, Hodges TR, Huse J, Zhou S, Xiu J, Spetzler D, Sanai N, Kim L, Kesari S, Brenner A, De Monte F, Heimberger A, Raza SMJournal of neuro-oncologyMultiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design. J Neurooncol. 2018 Sep; 139(2):469-478.J Neurooncol2018-05-30T00:00:002018Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.29572535Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, Toussaint B, Levenberg S, Wang J, Xiao N, Greil R, Rinnerthaler G, Gampenrieder SP, Heimberger AB, Berry DA, Barker A, Quackenbush J, Marshall JL, Poste G, Vacirca JL, Vidal GA, Schwartzberg LS, Halbert DD, Voss A, Magee D, Miglarese MR, Famulok M, Mayer G, Spetzler DNature communicationsPoly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. Nat Commun. 2018 03 23; 9(1):1219.Nat Commun2018-03-23T00:00:002018Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.29487694Ferguson SD, Zhou S, Xiu J, Hashimoto Y, Sanai N, Kim L, Kesari S, de Groot J, Spetzler D, Heimberger ABOncotargetEpendymomas overexpress chemoresistance and DNA repair-related proteins. Oncotarget. 2018 Jan 30; 9(8):7822-7831.Oncotarget2017-12-15T00:00:002017Ependymomas overexpress chemoresistance and DNA repair-related proteins.29632728Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, Wang F, Hawke D, Yu J, Healy LM, Hossain A, Akers JC, Maiti SN, Yamashita S, Shimizu Y, Dunner K, Zal MA, Burks JK, Gumin J, Nwajei F, Rezavanian A, Zhou S, Rao G, Sawaya R, Fuller GN, Huse JT, Antel JP, Li S, Cooper L, Sulman EP, Chen C, Geula C, Kalluri R, Zal T, Heimberger ABOncoimmunologyGlioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology. 2018; 7(4):e1412909.Oncoimmunology2018-01-16T00:00:002018Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes.29648659Caruso H, Heimberger ABNeuro-oncologyComment on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma". Neuro Oncol. 2018 06 18; 20(7):1003-1004.Neuro Oncol2018-06-18T00:00:002018Comment on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma".29869738Hashimoto Y, Penas-Prado M, Zhou S, Wei J, Khatua S, Hodges TR, Sanai N, Xiu J, Gatalica Z, Kim L, Kesari S, Rao G, Spetzler D, Heimberger AJournal of neuro-oncologyRethinking medulloblastoma from a targeted therapeutics perspective. J Neurooncol. 2018 Sep; 139(3):713-720.J Neurooncol2018-06-05T00:00:002018Rethinking medulloblastoma from a targeted therapeutics perspective.29923182Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger ABInternational journal of cancerProfiles of brain metastases: Prioritization of therapeutic targets. Int J Cancer. 2018 12 01; 143(11):3019-3026.Int J Cancer2018-10-09T00:00:002018Profiles of brain metastases: Prioritization of therapeutic targets.29991446Noh H, Zhao Q, Yan J, Kong LY, Gabrusiewicz K, Hong S, Xia X, Heimberger AB, Li SCancer lettersCell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Lett. 2018 10 01; 433:176-185.Cancer Lett2018-07-06T00:00:002018Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells.30307407Wei J, Marisetty A, Schrand B, Gabrusiewicz K, Hashimoto Y, Ott M, Grami Z, Kong LY, Ling X, Caruso H, Zhou S, Wang YA, Fuller GN, Huse J, Gilboa E, Kang N, Huang X, Verhaak R, Li S, Heimberger ABThe Journal of clinical investigationOsteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest. 2019 01 02; 129(1):137-149.J Clin Invest2018-11-19T00:00:002018Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target.29718398Ferguson SD, Zhou S, Huse JT, de Groot JF, Xiu J, Subramaniam DS, Mehta S, Gatalica Z, Swensen J, Sanai N, Spetzler D, Heimberger ABJournal of neuropathology and experimental neurologyTargetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. J Neuropathol Exp Neurol. 2018 06 01; 77(6):437-442.J Neuropathol Exp Neurol2018-06-01T00:00:002018Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas.29947810Latha K, Yan J, Yang Y, Gressot LV, Kong LY, Manyam G, Ezhilarasan R, Wang Q, Sulman EP, Eric Davis R, Huang S, Fuller GN, Rao A, Heimberger AB, Li S, Rao GJournal of the National Cancer InstituteThe Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. J Natl Cancer Inst. 2019 03 01; 111(3):292-300.J Natl Cancer Inst2019-03-01T00:00:002019The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma.30683885Yan J, Zhao Q, Gabrusiewicz K, Kong LY, Xia X, Wang J, Ott M, Xu J, Davis RE, Huo L, Rao G, Sun SC, Watowich SS, Heimberger AB, Li SNature communicationsFGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nat Commun. 2019 01 25; 10(1):448.Nat Commun2019-01-25T00:00:002019FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation.D005909Disorders40318030.447986GlioblastomaNeurosurgeryPathologyDepartment of NeurosurgeryNeurosurgeryBaylor College of MedicineFREDERICKLANGFREDERICK LANG29.70706480000000-95.397162400000001037LANG, FREDERICKAdjunct ProfessorAuthorship 9412206Authorship 94198014Authorship 942457930847840Ferguson SD, Bindal S, Bassett RL, Haydu LE, McCutcheon IE, Heimberger AB, Li J, O'Brien BJ, Guha-Thakurta N, Tetzlaff MT, Tawbi H, Davies MA, Glitza ICJournal of neuro-oncologyPredictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neurooncol. 2019 May; 142(3):499-509.J Neurooncol2019-03-07T00:00:002019Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).30770835Yan J, Zhao Q, Gabrusiewicz K, Kong LY, Xia X, Wang J, Ott M, Xu J, Davis RE, Huo L, Rao G, Sun SC, Watowich SS, Heimberger AB, Li SNature communicationsAuthor Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nat Commun. 2019 02 15; 10(1):862.Nat Commun2019-02-15T00:00:002019Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation.30799490Al-Holou WN, Hodges TR, Everson RG, Freeman J, Zhou S, Suki D, Rao G, Ferguson SD, Heimberger AB, McCutcheon IE, Prabhu SS, Lang FF, Weinberg JS, Wildrick DM, Sawaya RNeurosurgeryPerilesional Resection of Glioblastoma Is Independently Associated With Improved Outcomes. Neurosurgery. 2020 01 01; 86(1):112-121.Neurosurgery2020-01-01T00:00:002020Perilesional Resection of Glioblastoma Is Independently Associated With Improved Outcomes.23636127Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, Yang Y, McEnery K, Jethwa K, Gjyshi O, Qiao W, Levine NB, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger ABCancer researchmiR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res. 2013 Jul 01; 73(13):3913-26.Cancer Res2013-05-01T00:00:002013miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma.23983766Wei J, Gabrusiewicz K, Heimberger AClinical & developmental immunologyThe controversial role of microglia in malignant gliomas. Clin Dev Immunol. 2013; 2013:285246.Clin Dev Immunol2013-07-24T00:00:002013The controversial role of microglia in malignant gliomas.23993863Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, Aldape KCancer cellMesenchymal differentiation mediated by NF-?B promotes radiation resistance in glioblastoma. Cancer Cell. 2013 Sep 09; 24(3):331-46.Cancer Cell2013-08-29T00:00:002013Mesenchymal differentiation mediated by NF-?B promotes radiation resistance in glioblastoma.Authorship 948212431167575Patel R, Traylor JI, Latha K, Heimberger AB, Li S, Rao GExpert opinion on therapeutic targetsFibrinogen-like protein 2: a potential molecular target for glioblastoma treatment. Expert Opin Ther Targets. 2019 08; 23(8):647-649.Expert Opin Ther Targets2019-06-05T00:00:002019Fibrinogen-like protein 2: a potential molecular target for glioblastoma treatment.Authorship 957777231646067Caruso HG, Heimberger AB, Cooper LJNOncoimmunologySteering CAR T cells to distinguish friend from foe. Oncoimmunology. 2019; 8(10):e1271857.Oncoimmunology2018-08-06T00:00:002018Steering CAR T cells to distinguish friend from foe.Authorship 96044610Authorship 960530831686330Caruso HG, Tanaka R, Liang J, Ling X, Sabbagh A, Henry VK, Collier TL, Heimberger ABJournal of neuro-oncologyShortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function. J Neurooncol. 2019 Dec; 145(3):429-439.J Neurooncol2019-11-04T00:00:002019Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function.31679017Wei J, Chen P, Gupta P, Ott M, Zamler D, Kassab C, Bhat KP, Curran MA, de Groot JF, Heimberger ABNeuro-oncologyImmune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro Oncol. 2020 02 20; 22(2):180-194.Neuro Oncol2020-02-20T00:00:002020Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications.Authorship 960876731712784Kassab C, Zamler D, Kamiya-Matsuoka C, Gatalica Z, Xiu J, Spetzler D, Heimberger ABClinical oncology and researchGenetic and immune profiling for potential therapeutic targets in adult human craniopharyngioma. Clin Oncol Res. 2019; 2(3):2-8.Clin Oncol Res2019-06-27T00:00:002019Genetic and immune profiling for potential therapeutic targets in adult human craniopharyngioma.Authorship 9614403031755915de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger ABNeuro-oncologyWindow-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.Neuro Oncol2020-04-15T00:00:002020Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.Authorship 9746521331873309Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma PNature medicineImmune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 01; 26(1):39-46.Nat Med2019-12-23T00:00:002019Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.Authorship 976194331967642Rao G, Sonabend A, Heimberger ABNeuro-oncologyAre radiation and response biomarkers the missing elements for efficacious immunotherapy for glioma patients? Neuro Oncol. 2020 05 15; 22(5):590-591.Neuro Oncol2020-05-15T00:00:002020Are radiation and response biomarkers the missing elements for efficacious immunotherapy for glioma patients?Authorship 9778552932049048Amin SB, Anderson KJ, Boudreau CE, Martinez-Ledesma E, Kocakavuk E, Johnson KC, Barthel FP, Varn FS, Kassab C, Ling X, Kim H, Barter M, Lau CC, Ngan CY, Chapman M, Koehler JW, Long JP, Miller AD, Miller CR, Porter BF, Rissi DR, Mazcko C, LeBlanc AK, Dickinson PJ, Packer RA, Taylor AR, Rossmeisl JH, Woolard KD, Heimberger AB, Levine JM, Verhaak RGWCancer cellComparative Molecular Life History of Spontaneous Canine and Human Gliomas. Cancer Cell. 2020 02 10; 37(2):243-257.e7.Cancer Cell2020-02-10T00:00:002020Comparative Molecular Life History of Spontaneous Canine and Human Gliomas.Authorship 978668432112296Beccaria K, Sabbagh A, de Groot J, Canney M, Carpentier A, Heimberger ABJournal of neuro-oncologyBlood-brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors. J Neurooncol. 2021 Jan; 151(1):65-73.J Neurooncol2020-02-28T00:00:002020Blood-brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors.Authorship 98019314Authorship 9801991932201861Ou A, Sumrall A, Phuphanich S, Spetzler D, Gatalica Z, Xiu J, Michelhaugh S, Brenner A, Pandey M, Kesari S, Korn WM, Mittal S, Westin J, Heimberger ABNeuro-oncology advancesPrimary CNS lymphoma commonly expresses immune response biomarkers. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa018.Neurooncol Adv2020-02-19T00:00:002020Primary CNS lymphoma commonly expresses immune response biomarkers.32202512Zhou X, He C, Ren J, Dai C, Stevens SR, Wang Q, Zamler D, Shingu T, Yuan L, Chandregowda CR, Wang Y, Ravikumar V, Rao AU, Zhou F, Zheng H, Rasband MN, Chen Y, Lan F, Heimberger AB, Segal BM, Hu JThe Journal of clinical investigationMature myelin maintenance requires Qki to coactivate PPAR?-RXRa-mediated lipid metabolism. J Clin Invest. 2020 05 01; 130(5):2220-2236.J Clin Invest2020-05-01T00:00:002020Mature myelin maintenance requires Qki to coactivate PPAR?-RXRa-mediated lipid metabolism.true1Adjunct ProfessorAdjunct ProfessorAuthorship 9866872932265228Liang J, Wang L, Wang C, Shen J, Su B, Marisetty AL, Fang D, Kassab C, Jeong KJ, Zhao W, Lu Y, Jain AK, Zhou Z, Liang H, Sun SC, Lu C, Xu ZX, Yu Q, Shao S, Chen X, Gao M, Claret FX, Ding Z, Chen J, Chen P, Barton MC, Peng G, Mills GB, Heimberger ABCancer immunology researchVerteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy. Cancer Immunol Res. 2020 07; 8(7):952-965.Cancer Immunol Res2020-04-07T00:00:002020Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy.Authorship 9875122532299815Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, Bdiwi M, Shaim H, Alsuliman A, Shanley M, de Groot JF, O'Brien BJ, Harrison R, Majd N, Kamiya-Matsuoka C, Fuller GN, Huse JT, Chi L, Rao G, Weinberg JS, Lang FF, Sawaya R, Shpall EJ, Rezvani K, Heimberger ABClinical cancer research : an official journal of the American Association for Cancer ResearchGlioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577.Clin Cancer Res2020-04-16T00:00:002020Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.Authorship 9897581732430477Kane JR, Zhao J, Tsujiuchi T, Laffleur B, Arrieta VA, Mahajan A, Rao G, Mela A, Dmello C, Chen L, Zhang DY, Gonz?lez-Buendia E, Lee-Chang C, Xiao T, Rothschild G, Basu U, Horbinski C, Lesniak MS, Heimberger AB, Rabadan R, Canoll P, Sonabend AMClinical cancer research : an official journal of the American Association for Cancer ResearchCD8+ T-cell-Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas. Clin Cancer Res. 2020 08 15; 26(16):4390-4401.Clin Cancer Res2020-05-19T00:00:002020CD8+ T-cell-Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas.Authorship 99210518Authorship 9924481232554515Rao G, Latha K, Ott M, Sabbagh A, Marisetty A, Ling X, Zamler D, Doucette TA, Yang Y, Kong LY, Wei J, Fuller GN, Benavides F, Sonabend AM, Long J, Li S, Curran M, Heimberger ABClinical cancer research : an official journal of the American Association for Cancer ResearchAnti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. Clin Cancer Res. 2020 09 01; 26(17):4699-4712.Clin Cancer Res2020-06-18T00:00:002020Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.32567735Dumas AA, Pomella N, Rosser G, Guglielmi L, Vinel C, Millner TO, Rees J, Aley N, Sheer D, Wei J, Marisetty A, Heimberger AB, Bowman RL, Brandner S, Joyce JA, Marino SThe EMBO journalMicroglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment. EMBO J. 2020 08 03; 39(15):e103790.EMBO J2020-06-22T00:00:002020Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment.Authorship 9930862032605912Ott M, Kassab C, Marisetty A, Hashimoto Y, Wei J, Zamler D, Leu JS, Tomaszowski KH, Sabbagh A, Fang D, Gupta P, Priebe W, Zielinski RJ, Burks JK, Long JP, Kong LY, Fuller GN, DeGroot J, Sulman EP, Heimberger ABClinical cancer research : an official journal of the American Association for Cancer ResearchRadiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. Clin Cancer Res. 2020 09 15; 26(18):4983-4994.Clin Cancer Res2020-06-30T00:00:002020Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy.Authorship 9955722332721947Ott M, Tomaszowski KH, Marisetty A, Kong LY, Wei J, Duna M, Blumberg K, Ji X, Jacobs C, Fuller GN, Langford LA, Huse JT, Long JP, Hu J, Li S, Weinberg JS, Prabhu SS, Sawaya R, Ferguson S, Rao G, Lang FF, Curran MA, Heimberger ABJCI insightProfiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. JCI Insight. 2020 09 03; 5(17).JCI Insight2020-09-03T00:00:002020Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration.Authorship 9960861532750703Mohan R, Liu AY, Brown PD, Mahajan A, Dinh J, Chung C, McAvoy S, McAleer MF, Lin SH, Li J, Ghia AJ, Zhu C, Sulman EP, de Groot JF, Heimberger AB, McGovern SL, Grassberger C, Shih H, Ellsworth S, Grosshans DRNeuro-oncologyProton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro Oncol. 2021 02 25; 23(2):284-294.Neuro Oncol2021-02-25T00:00:002021Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons.Authorship 9980533032847614Sa JK, Chang N, Lee HW, Cho HJ, Ceccarelli M, Cerulo L, Yin J, Kim SS, Caruso FP, Lee M, Kim D, Oh YT, Lee Y, Her NG, Min B, Kim HJ, Jeong DE, Kim HM, Kim H, Chung S, Woo HG, Lee J, Kong DS, Seol HJ, Lee JI, Kim J, Park WY, Wang Q, Sulman EP, Heimberger AB, Lim M, Park JB, Iavarone A, Verhaak RGW, Nam DHGenome biologyTranscriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. Genome Biol. 2020 08 26; 21(1):216.Genome Biol2020-08-26T00:00:002020Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma.Authorship 999473532921358Giridharan N, Glitza Oliva IC, O'Brien BJ, Parker Kerrigan BC, Heimberger AB, Ferguson SDNeurosurgery clinics of North AmericaTargeting the Tumor Microenvironment in Brain Metastasis. Neurosurg Clin N Am. 2020 Oct; 31(4):641-649.Neurosurg Clin N Am2020-10-01T00:00:002020Targeting the Tumor Microenvironment in Brain Metastasis.Authorship 10026649Authorship 1002932533067318Wang M, Jain P, Chi TL, Chen SE, Heimberger A, Weathers SP, Zheng L, Rao AV, Rossi JMJournal for immunotherapy of cancerManagement of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. J Immunother Cancer. 2020 10; 8(2).J Immunother Cancer2020-10-01T00:00:002020Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2.33045062Ren J, Dai C, Zhou X, Barnes JA, Chen X, Wang Y, Yuan L, Shingu T, Heimberger AB, Chen Y, Hu JThe Journal of experimental medicineQki is an essential regulator of microglial phagocytosis in demyelination. J Exp Med. 2021 01 04; 218(1).J Exp Med2021-01-04T00:00:002021Qki is an essential regulator of microglial phagocytosis in demyelination.Authorship 1006111333252666Khasraw M, Walsh KM, Heimberger AB, Ashley DMNeuro-oncologyWhat is the Burden of Proof for Tumor Mutational Burden in gliomas? Neuro Oncol. 2020 Nov 30.Neuro Oncol2020-11-30T00:00:002020What is the Burden of Proof for Tumor Mutational Burden in gliomas?Authorship 1007454733348707Marisetty A, Wei J, Kong LY, Ott M, Fang D, Sabbagh A, Heimberger ABCancersMiR-181 Family Modulates Osteopontin in Glioblastoma Multiforme. Cancers (Basel). 2020 Dec 17; 12(12).Cancers (Basel)2020-12-17T00:00:002020MiR-181 Family Modulates Osteopontin in Glioblastoma Multiforme.Authorship 1007846533367885Chuntova P, Chow F, Watchmaker PB, Galvez M, Heimberger AB, Newell EW, Diaz A, DePinho RA, Li MO, Wherry EJ, Mitchell D, Terabe M, Wainwright DA, Berzofsky JA, Herold-Mende C, Heath JR, Lim M, Margolin KA, Chiocca EA, Kasahara N, Ellingson BM, Brown CE, Chen Y, Fecci PE, Reardon DA, Dunn GP, Liau LM, Costello JF, Wick W, Cloughesy T, Timmer WC, Wen PY, Prins RM, Platten M, Okada HNeuro-oncologyUnique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2021 03 25; 23(3):356-375.Neuro Oncol2021-03-25T00:00:002021Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank.Authorship 10086752033426529Ferguson SD, Hodges TR, Majd NK, Alfaro-Munoz K, Al-Holou WN, Suki D, de Groot JF, Fuller GN, Xue L, Li M, Jacobs C, Rao G, Colen RR, Xiu J, Verhaak R, Spetzler D, Khasraw M, Sawaya R, Long JP, Heimberger ABNeuro-oncology advancesA validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdaa146.Neurooncol Adv2020-10-31T00:00:002020A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram.Authorship 1009955433498872Ou A, Ott M, Fang D, Heimberger ABCancersThe Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma. Cancers (Basel). 2021 Jan 24; 13(3).Cancers (Basel)2021-01-24T00:00:002021The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma.Authorship 1011165833571109Hu J, Zhao Q, Kong LY, Wang J, Yan J, Xia X, Jia Z, Heimberger AB, Li SScience advancesRegulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme. Sci Adv. 2021 01; 7(5).Sci Adv2021-01-27T00:00:002021Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme.Authorship 101256715Authorship 1012758433647972Brown PD, Chung C, Liu DD, McAvoy S, Grosshans D, Al Feghali K, Mahajan A, Li J, McGovern SL, McAleer MF, Ghia AJ, Sulman EP, Penas-Prado M, de Groot JF, Heimberger AB, Wang J, Armstrong TS, Gilbert MR, Guha-Thakurta N, Wefel JSNeuro-oncologyA prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. Neuro Oncol. 2021 08 02; 23(8):1337-1347.Neuro Oncol2021-08-02T00:00:002021A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma.33663953Xuan W, Lesniak MS, James CD, Heimberger AB, Chen PTrends in immunologyContext-Dependent Glioblastoma-Macrophage/Microglia Symbiosis and Associated Mechanisms. Trends Immunol. 2021 04; 42(4):280-292.Trends Immunol2021-03-01T00:00:002021Context-Dependent Glioblastoma-Macrophage/Microglia Symbiosis and Associated Mechanisms.Authorship 1013359933676940Yan J, Zhao Q, Wang J, Tian X, Wang J, Xia X, Ott M, Rao G, Heimberger AB, Li SCancer lettersFGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells. Cancer Lett. 2021 05 28; 506:83-94.Cancer Lett2021-03-04T00:00:002021FGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells.Authorship 10193141834031054Sabbagh A, Beccaria K, Ling X, Marisetty A, Ott M, Caruso H, Barton E, Kong LY, Fang D, Latha K, Zhang DY, Wei J, DeGroot J, Curran MA, Rao G, Hu J, Desseaux C, Bouchoux G, Canney M, Carpentier A, Heimberger ABClinical cancer research : an official journal of the American Association for Cancer ResearchOpening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models. Clin Cancer Res. 2021 08 01; 27(15):4325-4337.Clin Cancer Res2021-05-24T00:00:002021Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models.Authorship 1020917334117475Ott M, Prins RM, Heimberger ABNature reviews. Clinical oncologyThe immune landscape of common CNS malignancies: implications for immunotherapy. Nat Rev Clin Oncol. 2021 11; 18(11):729-744.Nat Rev Clin Oncol2021-06-11T00:00:002021The immune landscape of common CNS malignancies: implications for immunotherapy.Authorship 10213474734138753Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB, Uprety N, Wang F, Huang Y, Gabrusiewicz K, Miao Q, Dou J, Alsuliman A, Kerbauy LN, Acharya S, Mohanty V, Mendt M, Li S, Lu J, Wei J, Fowlkes NW, Gokdemir E, Ensley EL, Kaplan M, Kassab C, Li L, Ozcan G, Banerjee PP, Shen Y, Gilbert AL, Jones CM, Bdiwi M, Nunez-Cortes AK, Liu E, Yu J, Imahashi N, Muniz-Feliciano L, Li Y, Hu J, Draetta G, Marin D, Yu D, Mielke S, Eyrich M, Champlin RE, Chen K, Lang FF, Shpall EJ, Heimberger AB, Rezvani KThe Journal of clinical investigationTargeting the av integrin/TGF-? axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest. 2021 07 15; 131(14).J Clin Invest2021-07-15T00:00:002021Targeting the av integrin/TGF-? axis improves natural killer cell function against glioblastoma stem cells.Authorship 10270361834337411Al Feghali KA, Randall JW, Liu DD, Wefel JS, Brown PD, Grosshans DR, McAvoy SA, Farhat MA, Li J, McGovern SL, McAleer MF, Ghia AJ, Paulino AC, Sulman EP, Penas-Prado M, Wang J, de Groot J, Heimberger AB, Armstrong TS, Gilbert MR, Mahajan A, Guha-Thakurta N, Chung CNeuro-oncology advancesPhase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab073.Neurooncol Adv2021-06-01T00:00:002021Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment.Authorship 1027709934162346Dardis C, Donner D, Sanai N, Xiu J, Mittal S, Michelhaugh SK, Pandey M, Kesari S, Heimberger AB, Gatalica Z, Korn MW, Sumrall AL, Phuphanich SBMC neurologyGliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling. BMC Neurol. 2021 Jun 23; 21(1):231.BMC Neurol2021-06-23T00:00:002021Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling.Authorship 10283699Authorship 1028463334433652Boudreau CE, Najem H, Ott M, Horbinski C, Fang D, DeRay CM, Levine JM, Curran MA, Heimberger ABClinical cancer research : an official journal of the American Association for Cancer ResearchIntratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma. Clin Cancer Res. 2021 10 15; 27(20):5528-5535.Clin Cancer Res2021-08-25T00:00:002021Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma.34440802Najem H, Khasraw M, Heimberger ABCellsImmune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy. Cells. 2021 08 09; 10(8).Cells2021-08-09T00:00:002021Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy.Authorship 1029929434532286Wei J, Gilboa E, Calin GA, Heimberger ABFrontiers in oncologyImmune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment. Front Oncol. 2021; 11:682129.Front Oncol2021-08-31T00:00:002021Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment.Authorship 10303492434561270Singh K, Batich KA, Wen PY, Tan AC, Bagley SJ, Lim M, Platten M, Colman H, Ashley DM, Chang SM, Rahman R, Galanis E, Mansouri A, Puduvalli VK, Reardon DA, Sahebjam S, Sampson JH, Simes J, Berry DA, Zadeh G, Cloughesy TF, Mehta MP, Piantadosi S, Weller M, Heimberger AB, Khasraw MClinical cancer research : an official journal of the American Association for Cancer ResearchDesigning Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clin Cancer Res. 2022 02 15; 28(4):585-593.Clin Cancer Res2022-02-15T00:00:002022Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.Authorship 1031741634665646Khasraw M, Fujita Y, Lee-Chang C, Balyasnikova IV, Najem H, Heimberger ABAnnual review of medicineNew Approaches to Glioblastoma. Annu Rev Med. 2022 01 27; 73:279-292.Annu Rev Med2021-10-19T00:00:002021New Approaches to Glioblastoma.Authorship 103229513Authorship 1032577934691054Najem H, Marisetty A, Horbinski C, Long J, Huse JT, Glitza Oliva IC, Ferguson SD, Kumthekar PU, Wainwright DA, Chen P, Lesniak MS, Burks JK, Heimberger ABFrontiers in immunologyCD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease. Front Immunol. 2021; 12:745893.Front Immunol2021-10-08T00:00:002021CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease.34705519McGrail DJ, Pili? PG, Dai H, Lam TNA, Liang Y, Voorwerk L, Kok M, Zhang XH, Rosen JM, Heimberger AB, Peterson CB, Jonasch E, Lin SYScience translational medicineReplication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Sci Transl Med. 2021 Oct 27; 13(617):eabe6201.Sci Transl Med2021-10-27T00:00:002021Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers.Authorship 1035962634948178Arrieta VA, Najem H, Petrosyan E, Lee-Chang C, Chen P, Sonabend AM, Heimberger ABInternational journal of molecular sciencesThe Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia. Int J Mol Sci. 2021 Dec 13; 22(24).Int J Mol Sci2021-12-13T00:00:002021The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia.Authorship 103869124Authorship 103941136Authorship 10397823635121903Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C, Shilati J, Jaishankar D, Chen L, Gould A, Zhang D, Yuan J, Zhao W, Ling X, Burks JK, Laffleur B, Amidei C, Bruce JN, Lukas RV, Yamaguchi JT, Cieremans D, Rothschild G, Basu U, McCord M, Brat DJ, Zhang H, Cooper LAD, Zhang B, Sims P, Cloughesy TF, Prins R, Canoll P, Stupp R, Heimberger AB, Horbinski C, Iwamoto FM, Rabadan R, Sonabend AMNature cancerERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat Cancer. 2021 12; 2(12):1372-1386.Nat Cancer2021-11-29T00:00:002021ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.35149861Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C, Shilati J, Jaishankar D, Chen L, Gould A, Zhang D, Yuan J, Zhao W, Ling X, Burks JK, Laffleur B, Amidei C, Bruce JN, Lukas RV, Yamaguchi JT, Cieremans D, Rothschild G, Basu U, McCord M, Brat DJ, Zhang H, Cooper LAD, Zhang B, Sims P, Cloughesy TF, Prins R, Canoll P, Stupp R, Heimberger AB, Horbinski C, Iwamoto FM, Rabadan R, Sonabend AMNature cancerPublisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat Cancer. 2022 Mar; 3(3):373.Nat Cancer2022-03-01T00:00:002022Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.35316217Najem H, Ott M, Kassab C, Rao A, Rao G, Marisetty A, Sonabend AM, Horbinski C, Verhaak R, Shankar A, Krishnan SN, Varn FS, Arrieta VA, Gupta P, Ferguson SD, Huse JT, Fuller GN, Long JP, Winkowski DE, Freiberg BA, James CD, Platanias LC, Lesniak MS, Burks JK, Heimberger ABJCI insightCentral nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression. JCI Insight. 2022 05 09; 7(9).JCI Insight2022-05-09T00:00:002022Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression.Authorship 10437738Authorship 104403315Authorship 10447141935433114Wei J, Song R, Sabbagh A, Marisetty A, Shukla N, Fang D, Najem H, Ott M, Long J, Zhai L, Lesniak MS, James CD, Platanias L, Curran M, Heimberger ABOncoimmunologyCell-directed aptamer therapeutic targeting for cancers including those within the central nervous system. Oncoimmunology. 2022; 11(1):2062827.Oncoimmunology2022-04-13T00:00:002022Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system.35413115Xuan W, Hsu WH, Khan F, Dunterman M, Pang L, Wainwright DA, Ahmed AU, Heimberger AB, Lesniak MS, Chen PCancer immunology researchCircadian Regulator CLOCK Drives Immunosuppression in Glioblastoma. Cancer Immunol Res. 2022 06 03; 10(6):770-784.Cancer Immunol Res2022-06-03T00:00:002022Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma.35487217Low JT, Chandramohan V, Bowie ML, Brown MC, Waitkus MS, Briley A, Stevenson K, Fuller R, Reitman ZJ, Muscat AM, Hariharan S, Hostettler J, Danehower S, Baker A, Khasraw M, Wong NC, Gregory S, Nair SK, Heimberger A, Gromeier M, Bigner DD, Ashley DMCancer cellEpigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition. Cancer Cell. 2022 05 09; 40(5):439-440.Cancer Cell2022-04-28T00:00:002022Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition.Authorship 104602120Authorship 1046116335575067Groot J, Ott M, Wei J, Kassab C, Fang D, Najem H, O'Brien B, Weathers SP, Matsouka CK, Majd NK, Harrison RA, Fuller GN, Huse JT, Long JP, Sawaya R, Rao G, MacDonald TJ, Priebe W, DeCuypere M, Heimberger ABCNS oncologyA first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol. 2022 06 01; 11(2):CNS87.CNS Oncol2022-05-16T00:00:002022A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.35580289Vogelbaum MA, Li G, Heimberger AB, Lang FF, Fueyo J, Gomez-Manzano C, Sanai NAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingA Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-8.Am Soc Clin Oncol Educ Book2022-04-01T00:00:002022A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology.Authorship 1046712335624002Pang L, Khan F, Heimberger AB, Chen PTrends in cancerMechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma. Trends Cancer. 2022 10; 8(10):839-854.Trends Cancer2022-05-24T00:00:002022Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.Authorship 10470741635653194Zamler DB, Shingu T, Kahn LM, Huntoon K, Kassab C, Ott M, Tomczak K, Liu J, Li Y, Lai I, Zorilla-Veloz R, Yee C, Rai K, Kim BY, Watowich SS, Heimberger AB, Draetta GF, Hu JJCI insightImmune landscape of a genetically engineered murine model of glioma compared with human glioma. JCI Insight. 2022 06 22; 7(12).JCI Insight2022-06-22T00:00:002022Immune landscape of a genetically engineered murine model of glioma compared with human glioma.Authorship 1049859935784281Larkin CJ, Arrieta VA, Najem H, Li G, Zhang P, Miska J, Chen P, James CD, Sonabend AM, Heimberger ABFrontiers in immunologyMyeloid Cell Classification and Therapeutic Opportunities Within the Glioblastoma Tumor Microenvironment in the Single Cell-Omics Era. Front Immunol. 2022; 13:907605.Front Immunol2022-06-16T00:00:002022Myeloid Cell Classification and Therapeutic Opportunities Within the Glioblastoma Tumor Microenvironment in the Single Cell-Omics Era.Authorship 105466111Authorship 105623510Authorship 10580156Authorship 105646612Authorship 105579313Authorship 10575385Authorship 10558826Authorship 10618453Authorship 105546322Authorship 1059911936652630Petrosyan E, Fares J, Fernandez LG, Yeeravalli R, Dmello C, Duffy JT, Zhang P, Lee-Chang C, Miska J, Ahmed AU, Sonabend AM, Balyasnikova IV, Heimberger AB, Lesniak MSMolecular cancer research : MCREndoplasmic Reticulum Stress in the Brain Tumor Immune Microenvironment. Mol Cancer Res. 2023 05 01; 21(5):389-396.Mol Cancer Res2023-05-01T00:00:002023Endoplasmic Reticulum Stress in the Brain Tumor Immune Microenvironment.35976058Youngblood MW, Tran AN, Wang W, An S, Scholtens D, Zhang L, O'Shea K, Pokorny JL, Magill ST, Sachdev S, Lukas RV, Ahmed A, Unruh D, Walshon J, McCortney K, Wang Y, Baran A, Sahm F, Aldape K, Chandler JP, David James C, Heimberger AB, Horbinski CNeuro-oncologyDocetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas. Neuro Oncol. 2023 03 14; 25(3):508-519.Neuro Oncol2023-03-14T00:00:002023Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas.36324813Tripathi S, Najem H, Mahajan AS, Zhang P, Low JT, Stegh AH, Curran MA, Ashley DM, James CD, Heimberger ABF1000ResearchcGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma. F1000Res. 2022; 11:1010.F1000Res2022-09-07T00:00:002022cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma.36647828Arrieta VA, Dmello C, McGrail DJ, Brat DJ, Lee-Chang C, Heimberger AB, Chand D, Stupp R, Sonabend AMThe Journal of clinical investigationImmune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J Clin Invest. 2023 01 17; 133(2).J Clin Invest2023-01-17T00:00:002023Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment.36011015Cao TQ, Wainwright DA, Lee-Chang C, Miska J, Sonabend AM, Heimberger AB, Lukas RVCancersNext Steps for Immunotherapy in Glioblastoma. Cancers (Basel). 2022 Aug 20; 14(16).Cancers (Basel)2022-08-20T00:00:002022Next Steps for Immunotherapy in Glioblastoma.36250346Khan AB, Lee S, Harmanci AS, Patel R, Latha K, Yang Y, Marisetty A, Lee HK, Heimberger AB, Fuller GN, Deneen B, Rao GInternational journal of cancerCXCR4 expression is associated with proneural-to-mesenchymal transition in glioblastoma. Int J Cancer. 2023 02 15; 152(4):713-724.Int J Cancer2022-10-31T00:00:002022CXCR4 expression is associated with proneural-to-mesenchymal transition in glioblastoma.36085259Zhang S, Rao G, Heimberger A, Li SCytokine & growth factor reviewsFibrinogen-like protein 2: Its biological function across cell types and the potential to serve as an immunotherapy target for brain tumors. Cytokine Growth Factor Rev. 2023 02; 69:73-79.Cytokine Growth Factor Rev2022-09-02T00:00:002022Fibrinogen-like protein 2: Its biological function across cell types and the potential to serve as an immunotherapy target for brain tumors.36705543Chen CH, Chin RL, Hartley GP, Lea ST, Engel BJ, Hsieh CE, Prasad R, Roszik J, Shingu T, Lizee GA, Heimberger AB, Millward SW, Hu J, Hong DS, Curran MANeuro-oncologyNovel murine glioblastoma models that reflect the immunotherapy resistance profile of a human disease. Neuro Oncol. 2023 08 03; 25(8):1415-1427.Neuro Oncol2023-08-03T00:00:002023Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human disease.36594466Khan F, Pang L, Dunterman M, Lesniak MS, Heimberger AB, Chen PThe Journal of clinical investigationMacrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. J Clin Invest. 2023 01 03; 133(1).J Clin Invest2023-01-03T00:00:002023Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy.35937580Pudakalakatti S, Audia A, Mukhopadhyay A, Enriquez JS, Bourgeois D, Tayob N, Zacharias NM, Millward SW, Carson D, Farach-Carson MC, Lang FF, Heimberger AB, Bhat KP, Bhattacharya PKReports (MDPI)NMR Spectroscopy-Based Metabolomics of Platelets to Analyze Brain Tumors. Reports (MDPI). 2021 Dec; 4(4).Reports (MDPI)2021-10-01T00:00:002021NMR Spectroscopy-Based Metabolomics of Platelets to Analyze Brain Tumors.Authorship 10635901536759517Zhao Q, Hu J, Kong L, Jiang S, Tian X, Wang J, Hashizume R, Jia Z, Fowlkes NW, Yan J, Xia X, Yi SF, Dao LH, Masopust D, Heimberger AB, Li SNature communicationsFGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells. Nat Commun. 2023 02 10; 14(1):735.Nat Commun2023-02-10T00:00:002023FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells.Authorship 10645391336831427Liang J, Fang D, Gumin J, Najem H, Sooreshjani M, Song R, Sabbagh A, Kong LY, Duffy J, Balyasnikova IV, Pollack SM, Puduvalli VK, Heimberger ABCancersA Case Study of Chimeric Antigen Receptor T Cell Function: Donor Therapeutic Differences in Activity and Modulation with Verteporfin. Cancers (Basel). 2023 Feb 08; 15(4).Cancers (Basel)2023-02-08T00:00:002023A Case Study of Chimeric Antigen Receptor T Cell Function: Donor Therapeutic Differences in Activity and Modulation with Verteporfin.Authorship 106597914Authorship 10660722436399711Burdett KB, Unruh D, Drumm M, Steffens A, Lamano J, Judkins J, Schwartz M, Javier R, Amidei C, Lipp ES, Peters KB, Lai A, Eldred BSC, Heimberger AB, McCortney K, Scholtens DM, Horbinski CBloodDetermining venous thromboembolism risk in patients with adult-type diffuse glioma. Blood. 2023 03 16; 141(11):1322-1336.Blood2023-03-16T00:00:002023Determining venous thromboembolism risk in patients with adult-type diffuse glioma.36949040Dmello C, Zhao J, Chen L, Gould A, Castro B, Arrieta VA, Zhang DY, Kim KS, Kanojia D, Zhang P, Miska J, Yeeravalli R, Habashy K, Saganty R, Kang SJ, Fares J, Liu C, Dunn G, Bartom E, Schipma MJ, Hsu PD, Alghamri MS, Lesniak MS, Heimberger AB, Rabadan R, Lee-Chang C, Sonabend AMNature communicationsCheckpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. Nat Commun. 2023 03 22; 14(1):1566.Nat Commun2023-03-22T00:00:002023Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade.Authorship 1068547237115694Goethe EA, Heimberger AB, Rao GThe Journal of clinical investigationAspirin and immunotherapy: a Faustian bargain? J Clin Invest. 2023 05 01; 133(9).J Clin Invest2023-05-01T00:00:002023Aspirin and immunotherapy: a Faustian bargain?Authorship 10740301937104042Drumm MR, Wang W, Sears TK, Bell-Burdett K, Javier R, Cotton KY, Webb B, Byrne K, Unruh D, Thirunavu V, Walshon J, Steffens A, McCortney K, Lukas RV, Phillips JJ, Mohamed E, Finan JD, Santana-Santos L, Heimberger AB, Franz CK, Kurz J, Templer JW, Swanson GT, Horbinski CThe Journal of clinical investigationPostoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors. J Clin Invest. 2023 06 15; 133(12).J Clin Invest2023-06-15T00:00:002023Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors.Authorship 10803271036795563Pang L, Dunterman M, Xuan W, Gonzalez A, Lin Y, Hsu WH, Khan F, Hagan RS, Muller WA, Heimberger AB, Chen PCell reportsCircadian regulator CLOCK promotes tumor angiogenesis in glioblastoma. Cell Rep. 2023 02 28; 42(2):112127.Cell Rep2023-02-14T00:00:002023Circadian regulator CLOCK promotes tumor angiogenesis in glioblastoma.Authorship 10818267Authorship 108171710Authorship 10817511837860079Gould A, Gonzales VAA, Dmello CC, Saganty R, Lukas RV, Zhang DY, Heimberger AB, Canney M, Carpentier A, Desseaux C, Bouchoux G, Stupp R, Sonabend AMAdvances in oncologyAdvances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas. Adv Oncol. 2023 May; 3(1):77-86.Adv Oncol2023-04-07T00:00:002023Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas.37847564Fares J, Petrosyan E, Kanojia D, Dmello C, Cordero A, Duffy JT, Yeeravalli R, Sahani MH, Zhang P, Rashidi A, Arrieta VA, Ulasov I, Ahmed AU, Miska J, Balyasnikova IV, James CD, Sonabend AM, Heimberger AB, Lesniak MSThe Journal of clinical investigationMetixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases. J Clin Invest. 2023 Dec 15; 133(24).J Clin Invest2023-12-15T00:00:002023Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases.37841696Sim HW, Wachsmuth L, Barnes EH, Yip S, Koh ES, Hall M, Jennens R, Ashley DM, Verhaak RG, Heimberger AB, Rosenthal MA, Hovey EJ, Ellingson BM, Tognela A, Gan HK, Wheeler H, Back M, McDonald KL, Long A, Cuff K, Begbie S, Gedye C, Mislang A, Le H, Johnson MO, Kong BY, Simes JR, Lwin Z, Khasraw MNeuro-oncology advancesNUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad124.Neurooncol Adv2023-09-22T00:00:002023NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma.Authorship 10828503337805627Youngblood MW, Erson-Omay Z, Li C, Najem H, Co?kun S, Tyrtova E, Montejo JD, Miyagishima DF, Barak T, Nishimura S, Harmanci AS, Clark VE, Duran D, Huttner A, Avsar T, Bayri Y, Schramm J, Boetto J, Peyre M, Riche M, Goldbrunner R, Amankulor N, Louvi A, Bilg?var K, Pamir MN, ?zduman K, Kilic T, Knight JR, Simon M, Horbinski C, Kalamarides M, Timmer M, Heimberger AB, Mishra-Gorur K, Moliterno J, Yasuno K, G?nel MNature communicationsSuper-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas. Nat Commun. 2023 10 07; 14(1):6279.Nat Commun2023-10-07T00:00:002023Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas.Authorship 10833391837919784McCord M, Jamshidi P, Thirunavu V, Santana-Santos L, Vormittag-Nocito E, Dittman D, Parker S, Baczkowski J, Jennings L, Walshon J, McCortney K, Galbraith K, Zhang H, Lukas RV, Stupp R, Dixit K, Kumthekar P, Heimberger AB, Snuderl M, Horbinski CActa neuropathologica communicationsVariant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results. Acta Neuropathol Commun. 2023 11 02; 11(1):175.Acta Neuropathol Commun2023-11-02T00:00:002023Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results.Authorship 10866291138193532Tripathi S, Nathan CL, Tate MC, Horbinski CM, Templer JW, Rosenow JM, Sita TL, James CD, Deneen B, Miller SD, Heimberger ABJCI insightThe immune system and metabolic products in epilepsy and glioma-associated epilepsy: emerging therapeutic directions. JCI Insight. 2024 Jan 09; 9(1).JCI Insight2024-01-09T00:00:002024The immune system and metabolic products in epilepsy and glioma-associated epilepsy: emerging therapeutic directions.Authorship 10877591838268923Hou D, Wan H, Katz JL, Wang S, Castro BA, Vazquez-Cervantes GI, Arrieta VA, Dhiantravan S, Najem H, Rashidi A, Chia TY, Arjmandi T, Collado J, Billingham L, Lopez-Rosas A, Han Y, Sonabend AM, Heimberger AB, Zhang P, Miska J, Lee-Chang CFrontiers in immunologyAntigen-presenting B cells promote TCF-1+ PD1- stem-like CD8+ T-cell proliferation in glioblastoma. Front Immunol. 2023; 14:1295218.Front Immunol2024-01-10T00:00:002024Antigen-presenting B cells promote TCF-1+ PD1- stem-like CD8+ T-cell proliferation in glioblastoma.Authorship 108892028Authorship 1089027838357919Tripathi S, Najem H, Dussold C, Pacheco S, Miska J, McCortney K, Steffens A, Walshon J, Winkowski D, Cloney M, Ordon M, Gibson W, Kemeny H, Youngblood M, Du R, Mossner J, Texakalidis P, Sprau A, Tate M, James CD, Horbinski CM, Wadhwani NR, Lesniak MS, Lam S, Sati A, Aghi M, DeCuypere M, Heimberger ABThe Journal of clinical investigationCancer-associated fibroblast-secreted collagen is associated with immune inhibitor receptor LAIR1 in gliomas. J Clin Invest. 2024 Feb 15; 134(4).J Clin Invest2024-02-15T00:00:002024Cancer-associated fibroblast-secreted collagen is associated with immune inhibitor receptor LAIR1 in gliomas.38346200Kudruk S, Forsyth CM, Dion MZ, Hedlund Orbeck JK, Luo J, Klein RS, Kim AH, Heimberger AB, Mirkin CA, Stegh AH, Artzi NProceedings of the National Academy of Sciences of the United States of AmericaMultimodal neuro-nanotechnology: Challenging the existing paradigm in glioblastoma therapy. Proc Natl Acad Sci U S A. 2024 Feb 20; 121(8):e2306973121.Proc Natl Acad Sci U S A2024-02-12T00:00:002024Multimodal neuro-nanotechnology: Challenging the existing paradigm in glioblastoma therapy.Authorship 10914451438515188Humphries W, Wang Y, Qiao W, Reina-Ortiz C, Abou-Ghazal MK, Crutcher LM, Wei J, Kong LY, Sawaya R, Rao G, Weinberg J, Prabhu SS, Fuller GN, Heimberger ABJournal of translational medicineCorrection: Detecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. J Transl Med. 2024 Mar 21; 22(1):296.J Transl Med2024-03-21T00:00:002024Correction: Detecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professor24409449Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M, Heimberger ABCancer immunology researchImmune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res. 2013 Aug; 1(2):112-22.Cancer Immunol Res2013-08-01T00:00:002013Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas.24974128Xu S, Wei J, Wang F, Kong LY, Ling XY, Nduom E, Gabrusiewicz K, Doucette T, Yang Y, Yaghi NK, Fajt V, Levine JM, Qiao W, Li XG, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger ABJournal of the National Cancer InstituteEffect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. J Natl Cancer Inst. 2014 Aug; 106(8).J Natl Cancer Inst2014-06-28T00:00:002014Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma.24938283Schrand B, Berezhnoy A, Brenneman R, Williams A, Levay A, Kong LY, Rao G, Zhou S, Heimberger AB, Gilboa ECancer immunology researchTargeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy. Cancer Immunol Res. 2014 Sep; 2(9):867-77.Cancer Immunol Res2014-06-17T00:00:002014Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.